Cytokinetics Inc (NAS:CYTK)
$ 48.98 -10.25 (-17.31%) Market Cap: 5.14 Bil Enterprise Value: 6.35 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Q1 2021 Cytokinetics Inc Earnings Call Transcript

May 06, 2021 / 08:30PM GMT
Release Date Price: $23.37 (-0.89%)
Operator

Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics' First Quarter 2021 Conference Call. At this time, I'd like to inform you that this call is being recorded (Operator Instructions)

I'd now like to turn the call over to Diane Weiser, Cytokinetics' Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.

Diane Weiser
Cytokinetics, Incorporated - SVP of Corporate Communications & IR

Good afternoon, and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will kick off the call with an overview of the quarter and recent developments. Then Fady Malik, our EVP of Research and Development, will provide an update on omecamtiv mecarbil, including progress following a recent meeting with FDA and what to expect from upcoming analyses from GALACTIC-HF, the positive Phase III clinical trial of omecamtiv mecarbil as well as recent activities related to METEORIC-HF, the second Phase III clinical trial of omecamtiv mecarbil.

Next, Stuart Kupfer, our SVP and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot